Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study.
Chenyu ShenWenxi JiangRuiqing ChenLingbing LiYunbo WuLong TanYadong ChenWeiqiang ZhangZhijun WangPublished in: Journal of cancer research and clinical oncology (2024)
The combination therapy of TACE, sintilimab, and lenvatinib demonstrates satisfactory efficacy in the treatment of uHCC with manageable tr-AEs.